In 1986 Ole Rafaelsen and William Bunney were instrumental in establishing a CINP programme supporting the attendance of young scientists at the XVth CINP Congress in 1986. That programme was posthumously named the Rafaelsen Fellowship Award to honor Dr. Rafaelsen, who died in 1987.
The recipients of the award will be chosen by an international scientific jury. A number of awardees will be selected and presented with awards consisting of round trip economy air travel, up to four night's accommodation, a certificate, a cash stipend including an element for ground transportation and waived registration fees at the next International Meeting or World Congress. The selected recipients may also have the opportunity to present their poster as part of a Rafaelsen Young Investigators Travel Award Winners session under a new initiative within CINP.
The Young Investigator Award is open to individual's world-wide, independent of nationality, sex or race.
Applications must be sponsored by a CINP member.
Those nominated may be researchers or clinicians, but must have made a commitment to the field of neuropsychopharmacology.
Individuals must have a doctorate degree, be working full-time in neuropsychopharmacology research, teaching, or clinical activities, have not reached his/her 36th birthday in the year in which the award is made (i.e., no older than 35 years of age as of 31st December 2019).
Each Awardee must commit to present a poster at the Congress.
Awardee must commit to attendance for the entire duration of the Congress.
For more information and the application form, please visit the CINP website.
Rafaelsen Young Investigators Award Winners 2019
Zheng Chang is an assistant professor at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. He completed his PhD in psychiatric epidemiology at Karolinska Institutet in 2013, and did his postdoc at University of Oxford and University of Chicago afterwards. Zheng's research has focused on understanding the risks and benefits of prescribed psychotropic medications, particularly ADHD medications, using large population-based data. He has strong skills in advanced pharmacoepidemiology designs and statistical analyses. He has over 50 publications, including a number of papers published in leading medical and psychiatric journals.
Fredrik Hieronymus undertook his PhD studies at the University of Gothenburg. His PhD project focussed on evaluating the specific effects of selective serotonin reuptake inhibitor (SSRI) treatment when used for major depression. Through the use of individual patient-level data from a comprehensive collection of randomized controlled trials, it was found that the symptoms included in the Hamilton Depression Rating Scale (HDRS) demonstrate markedly different response trajectories over time, that much information is lost when converting item-level information into the HDRS sum-score, and that the HDRS sum-score underestimates antidepressant efficacy partly due to the inclusion of HDRS items that may reflect common SSRI side-effects. Fredrik Hieronymus is now a post-doctoral researcher at Aarhus University where he continues to study the efficacy and safety of pharmacological treatments for depression, bipolar disorder and psychosis.
Dr. Bin Zhang works as a Junior PI in the Affiliated Brain Hospital of Guangzhou Medical University.
He studied Medicine in Tianjin Medical University (China), and completed the Integrative Neuroscience Program and obtained his PhD degree at Otto von Guericke University of Magdeburg (Germany). His research focuses on emotion and cognition interaction and neuropsychopharmacology using functional and structural MRI. He has got three research grants of Chinese government to do psychiatric research, especially neuropsychopharmacology. He has published 18 peer review articles.